IFN-γ and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma

• Published in: Cells (Basel, Switzerland) Switzerland), 2022-04, Vol.11 (9), p.1514
• Main Authors: Homann, Lorenzo, Rentschler, Maximilian, Brenner, Ellen, Böhm, Katharina, Röcken, Martin, Wieder, Thomas
• Format: Article
• Language: English
• Subjects: CD4 antigen; CD8 antigen; CD8-Positive T-Lymphocytes - metabolism; Cell culture; Cell cycle; cell cycle inhibition; Cellular Senescence; Chemokines; Cyclin-dependent kinase inhibitor p21; Cyclin-dependent kinases; Cytokines; Cytokines - metabolism; Doxorubicin; Effector cells; Gene expression; GTP-binding protein; Humans; Immune checkpoint; Immunotherapy; interferon; Interferon-gamma - metabolism; Interferon-gamma - pharmacology; Kinases; Lymphocytes T; Melanoma; Melanoma - drug therapy; Metastasis; Phenotypes; Protein arrays; Proteins; SASP; Secretome; Senescence; Senescence-Associated Secretory Phenotype; Skin cancer; Tumor cells; Tumor Necrosis Factor-alpha - pharmacology; Tumor necrosis factor-TNF; Tumor necrosis factor-α; β-Galactosidase; γ-Interferon
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells11091514

Immune checkpoint blockade (ICB) therapy is a central pillar of melanoma treatment leading to durable response rates. Important mechanisms of action of ICB therapy include disinhibition of CD4 and CD8 T cells. Stimulated CD4 T helper 1 cells secrete the effector cytokines interferon-gamma (IFN-γ) and tumor necrosis factor alpha (TNF), which induce senescence in tumor cells. Besides being growth-arrested, senescent cells are metabolically active and secrete a large spectrum of factors, which are summarized as senescence-associated secretory phenotype (SASP). This secretome affects the tumor growth. Here, we compared the SASP of cytokine-induced senescent (CIS) cells with the SASP of therapy-induced senescent (TIS) cells. Therefore, we established in vitro models for CIS and TIS in melanoma. The human melanoma cell lines SK-MEL-28 and WM115 were treated with the cytokines IFN-γ and TNF as CIS, the chemotherapeutic agent doxorubicin, and the cell cycle inhibitor palbociclib as TIS. Then, we determined several senescence markers, i.e., growth arrest, p21 expression, and senescence-associated β-galactosidase (SA-β-gal) activity. For SASP analyses, we measured the regulation and secretion of several common SASP factors using qPCR arrays, protein arrays, and ELISA. Each treatment initiated a stable growth arrest, enhanced SA-β-gal activity, and-except palbociclib-increased the expression of p21. mRNA and protein analyses revealed that gene expression and secretion of SASP factors were severalfold stronger in CIS than in TIS. Finally, we showed that treatment with the conditioned media (CM) derived from cytokine- and palbociclib-treated cells induced senescence characteristics in melanoma cells. Thus, we conclude that senescence induction via cytokines may lead to self-sustaining senescence surveillance of melanoma.